Valuation : OLIPASS Corporation

Market Cap 26.53B 19.2M 16.48M 15.43M 14.13M 26.62M 1.83B 26.7M 183M 71.43M 924M 72.1M 70.54M 3.06B P/E 2021
-10.8x
P/E 2022 -7.66x
Enterprise Value 20.34B 14.72M 12.63M 11.83M 10.83M 20.4M 1.41B 20.46M 140M 54.75M 708M 55.26M 54.07M 2.34B EV / Sales 2021
295x
EV / Sales 2022 79x
Free-Float
48.85%
Yield 2021 *
-
Yield 2022 -
3 years 1,568
Extreme 1568
34,500
5 years 1,568
Extreme 1568
141,000
10 years 1,568
Extreme 1568
240,666.67
Manager TitleAgeSince
Chief Executive Officer 54 21/05/2025
Corporate Officer/Principal 34 27/11/2024
Comptroller/Controller/Auditor 67 30/03/2025
Director TitleAgeSince
Director/Board Member 54 27/11/2024
Director/Board Member 34 27/11/2024
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
-13.92%-.--%-.--%-91.74% 9.71M
+3.31%-3.70%+61.03%+103.64% 70.42B
+1.09%+2.51%+49.34%+93.23% 65.4B
-0.86%+0.49%+8.17%-7.66% 28.28B
-0.49%+5.43%+54.81%+13.87% 26.57B
-1.58%-2.28%-9.14%+465.36% 27.16B
+0.37%+1.21%+36.55%-17.60% 20.09B
+1.02%+6.43%+269.42%+420.34% 20.61B
+0.77%+0.19%+8.01%+520.34% 15.87B
-1.68%+2.74%+43.24%+148.69% 13.9B
Average -1.22%-3.54%+52.14%+164.85% 28.83B
Weighted average by Cap. +0.81%+0.72%+55.42%+155.47%

Financials

2021 2022
Net sales 852M 617K 529K 495K 454K 855K 58.88M 857K 5.87M 2.29M 29.68M 2.31M 2.26M 98.21M 2.3B 1.66M 1.43M 1.34M 1.22M 2.3M 159M 2.31M 15.81M 6.18M 79.99M 6.24M 6.1M 265M
Net income -25.13B -18.19M -15.62M -14.62M -13.39M -25.22M -1.74B -25.29M -173M -67.68M -876M -68.3M -66.83M -2.9B -24.17B -17.49M -15.02M -14.06M -12.87M -24.25M -1.67B -24.32M -166M -65.07M -842M -65.67M -64.26M -2.79B
Net Debt -18.29B -13.24M -11.36M -10.64M -9.74M -18.35M -1.26B -18.4M -126M -49.25M -637M -49.7M -48.63M -2.11B -6.2B -4.48M -3.85M -3.6M -3.3M -6.22M -428M -6.23M -42.67M -16.68M -216M -16.83M -16.47M -714M
Logo OLIPASS Corporation
OliPass Corp is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is mainly engaged in the development of non-opioid analgesics, amyotrophic lateral sclerosis (ALS) treatments, therapies for age-related macular degeneration, and diabetic retinopathy. In addition, the Company researches, develops and sells functional cosmetics through artificial gene platform technology.
Employees
-
  1. Stock Market
  2. Stocks
  3. A244460 Stock